Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial
Key Takeaways
- Phentermine is a sympathomimetic stimulant approved for short-term obesity treatment (typically 12 weeks). GLP-1 medications are incretin-based therapies approved for chronic weight management.
- GLP-1 medications produce substantially more weight loss (14-22% trial means) than phentermine alone (5-8 lb typical, ~2-5% body weight).
- Phentermine is much cheaper ($10-$30/month) but has a more restrictive cardiovascular safety profile.
- Side effects do not overlap: phentermine is stimulant-driven; GLP-1s are GI-driven.
- The two can be combined in some patients; phentermine-topiramate (Qsymia) is the FDA-approved combination option for chronic use.
Direct answer
Phentermine is a 1959-approved short-term obesity drug that works as a sympathomimetic appetite suppressant. GLP-1 medications (semaglutide, tirzepatide) are 21st-century incretin-based drugs approved for chronic weight management with substantially larger trial-documented weight loss. Phentermine is much cheaper and works quickly; GLP-1 produces more weight loss and is approved for long-term use. The choice depends on cost, comorbidities, weight-loss target, and tolerance for two different side effect profiles.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →Table of contents
- Two drug classes, two mechanisms
- Approval history: a 65-year gap
- Weight-loss magnitude
- Approved duration of use
- Side effect profiles side by side
- Cardiovascular considerations
- Cost: the most lopsided comparison
- Phentermine-topiramate (Qsymia) as the bridge
- Combining phentermine with GLP-1
- Insurance coverage patterns
- The contrary view: why phentermine still has a place
- Decision logic
- FAQ
- Sources
Two drug classes, two mechanisms
Phentermine (sympathomimetic):
- Chemical relative of amphetamine
- Stimulates release of norepinephrine from sympathetic nerve terminals
- Acts centrally in the hypothalamus to suppress appetite
- Also affects dopamine and serotonin to a lesser extent
- Schedule IV controlled substance under DEA classification (lower abuse potential than schedule II stimulants but still controlled)
GLP-1 medications (incretin-based):
- Peptide drugs (semaglutide, tirzepatide) modeled on the incretin hormone GLP-1
- Activate GLP-1 receptors in the gut, pancreas, and central nervous system
- Tirzepatide additionally activates the GIP receptor
- Slow gastric emptying, suppress glucagon, stimulate glucose-dependent insulin secretion, signal satiety
- Not controlled substances
The mechanisms are unrelated. A patient who fails one class because of mechanism-specific intolerance may succeed on the other.
Approval history: a 65-year gap
| Year | Drug | Indication |
|---|---|---|
| 1959 | Phentermine | Short-term obesity treatment (FDA approval) |
| 1985 | Phentermine HCl extended-release reformulations | Same indication, refined dosing |
| 1996-1997 | Fen-phen era (phentermine + fenfluramine off-label combination) | Withdrawn after cardiac valvulopathy concerns; fenfluramine removed from market |
| 2012 | Qsymia (phentermine + topiramate ER) | FDA-approved for chronic weight management |
| 2014 | Saxenda (liraglutide) | First GLP-1 approved for chronic weight management (daily injection) |
| 2021 | Wegovy (semaglutide) | FDA-approved for chronic weight management (weekly injection) |
| 2023 | Zepbound (tirzepatide) | FDA-approved for chronic weight management |
Phentermine has been on the U.S. market for over 65 years. The GLP-1 class has been available for obesity for about a decade in injectable form, with the major modern GLP-1 obesity drugs (Wegovy and Zepbound) approved in the 2020s. The comparison is between an old class with extensive historical use and a newer class with stronger modern trial data.
Weight-loss magnitude
| Drug | Mean weight loss | Duration | Source |
|---|---|---|---|
| Phentermine 15-37.5 mg/day | 5-8 lb (about 2-5% body weight) | 12 weeks | Phentermine label; meta-analyses |
| Qsymia 15/92 mg (phentermine + topiramate) | ~9-10% | 56 weeks | EQUIP trial (Allison 2012) |
| Semaglutide 2.4 mg (Wegovy) | ~14.9% | 68 weeks | STEP 1 (Wilding 2021) |
| Tirzepatide 15 mg (Zepbound) | ~22.5% | 72 weeks | SURMOUNT-1 (Jastreboff 2022) |
| Tirzepatide 15 mg vs Semaglutide 2.4 mg (head-to-head) | 20.2% vs 13.7% | 72 weeks | SURMOUNT-5 (Aronne 2025) |
The numerical ranking is consistent: tirzepatide > semaglutide > Qsymia > phentermine alone. The gap between phentermine and tirzepatide is roughly 4-fold in trial mean weight loss.
Approved duration of use
The FDA's approved duration is the cleanest distinction:
- Phentermine alone: short-term (typically up to 12 weeks)
- Qsymia (phentermine + topiramate): long-term/chronic
- Wegovy, Zepbound, Saxenda: long-term/chronic
The short-term restriction on phentermine alone reflects historical concerns about stimulant tolerance, cardiovascular effects, and abuse potential. In practice, off-label long-term phentermine use is common in obesity medicine, particularly when combined with topiramate (as separate prescriptions rather than fixed-dose Qsymia) or with GLP-1 medications. Off-label use is legal but not formally endorsed by the FDA label.
Side effect profiles side by side
| Side effect | Phentermine | GLP-1 medications |
|---|---|---|
| Nausea | Less common | Common (30-44% during titration) |
| Diarrhea | Less common | Common (20-30%) |
| Constipation | Less common | Common (15-24%) |
| Increased heart rate | Common (5-10 bpm typical) | Modest increase |
| Elevated blood pressure | Common | Modest decrease usually |
| Insomnia | Common | Uncommon |
| Dry mouth | Common | Less common |
| Anxiety, jitteriness | Common | Uncommon |
| Mood changes | Possible (mostly negative) | Variable |
| Pancreatitis | Not associated | Rare |
| Gallbladder events | Not associated | Increased risk |
| Thyroid C-cell concern | None | Black-box warning based on rodent data |
| Abuse potential | Schedule IV controlled | None |
The two profiles barely overlap. A patient struggling with GLP-1 nausea may tolerate phentermine well. A patient with cardiovascular contraindications to phentermine may have no issue with GLP-1.
Cardiovascular considerations
This is the largest safety-related divergence.
Phentermine cardiovascular profile:
- Causes resting heart rate increase, typically 5-10 bpm
- Causes blood pressure increase, typically 2-5 mmHg
- Contraindicated in uncontrolled hypertension, established cardiovascular disease, history of stroke, arrhythmia history, or hyperthyroidism
- Cardiac valvulopathy concerns from the fen-phen era reduced enthusiasm for the drug class for decades
- Long-term cardiovascular outcomes data is limited; large trials have not been conducted
GLP-1 cardiovascular profile:
- SUSTAIN-6 showed 26% MACE reduction with semaglutide in T2D with high CV risk
- SELECT showed 20% MACE reduction with semaglutide in obesity with established CVD without diabetes
- Slight resting heart rate increase noted (~2-4 bpm)
- Modest blood pressure reduction typical
- FDA cardiovascular indication for Wegovy in obesity with established CVD
For patients with cardiovascular comorbidities, GLP-1 medications are the safer and increasingly evidence-supported choice. For young, healthy patients without CV risk factors, phentermine's cardiovascular impact is generally tolerable.
Cost: the most lopsided comparison
| Medication | Typical monthly cost |
|---|---|
| Phentermine 37.5 mg generic (most common dose) | $10-$30 cash retail; often $0-$10 with insurance |
| Phentermine 15-30 mg generic | Similar range |
| Qsymia (phentermine + topiramate ER) | $200-$300 cash retail; with savings card $98-$200 |
| Compounded semaglutide | $150-$300 |
| Compounded tirzepatide | $250-$450 |
| Wegovy NovoCare Direct | $499 |
| Zepbound Lilly Direct vials (2.5-10 mg) | $349-$499 |
| Wegovy or Zepbound pen retail | ~$1,059-$1,349 |
Phentermine is one of the cheapest prescription medications available. The price gap between phentermine and GLP-1 is 10-100x depending on the GLP-1 product. For cost-driven patients, phentermine is a serious alternative even with its smaller weight-loss magnitude.
Phentermine-topiramate (Qsymia) as the bridge
Qsymia combines phentermine with topiramate, an anticonvulsant with separate appetite-suppressing properties. The combination:
- FDA-approved 2012 for chronic weight management
- Produces approximately 9-10% mean weight loss at 56 weeks (EQUIP trial)
- Available at four dose strengths (3.75/23, 7.5/46, 11.25/69, 15/92 mg)
- REMS program required (cardiac and pregnancy safety monitoring)
- Contraindicated in pregnancy due to topiramate teratogenicity
Qsymia's weight loss magnitude (9-10%) sits between phentermine alone (~3-5%) and semaglutide (~15%). For patients seeking pharmacotherapy without injection and at lower cost than GLP-1, Qsymia is a reasonable bridge option. Its cardiovascular profile inherits phentermine's concerns; its teratogenicity restricts use in women of reproductive age unless on reliable contraception.
Combining phentermine with GLP-1
The two drug classes have largely non-overlapping mechanisms and side effect profiles, making combination appealing in patients who have plateaued on one alone. Clinical practice patterns:
- Patient on GLP-1 monotherapy plateaus at moderate dose; clinician adds low-dose phentermine for additive appetite suppression
- Patient on phentermine for short-term loss transitions to GLP-1 for long-term maintenance; brief overlap during transition
- Patient with severe obesity uses both from the start to maximize early weight loss
Considerations for combination use:
- Monitor heart rate and blood pressure due to additive effects
- Phentermine's stimulant action may mask early GLP-1 side effects (or compound them in some patients)
- Insurance coverage typically covers each separately under different policies
- Both drugs require independent prescribing decisions; no fixed-dose combination exists
The combination is not FDA-approved as a specific regimen but is increasingly common in obesity medicine practice. Trial-level evidence for the combination is limited; clinical experience is more substantial.
Insurance coverage patterns
| Drug | Typical commercial coverage | Typical Medicare Part D coverage |
|---|---|---|
| Phentermine | Often covered with low copay; some plans require prior auth | Variable; some plans cover |
| Qsymia | Variable; often requires prior auth and BMI documentation | Rarely covered for obesity |
| Wegovy | Plan-dependent; obesity often excluded; CVD indication may make available coverage | Not covered for obesity; covered for CVD indication in some plans |
| Zepbound | Plan-dependent; obesity often excluded; OSA indication may make available coverage | Not covered for obesity; OSA pathway evolving |
Phentermine wins on coverage simplicity. GLP-1 medications wins on coverage depth when an indication match is achievable.
The contrary view: why phentermine still has a place
The trial-data ranking puts GLP-1 medications well ahead. Several scenarios still favor phentermine:
Argument 1: Cost-driven access.
For patients without insurance and limited ability to pay, phentermine at $10-$30/month is feasible when GLP-1 medications at $200-$1,300/month are not. A patient who would otherwise have no pharmacotherapy benefits from any effective option.
Argument 2: Rapid initial response.
Phentermine's appetite suppression begins within hours of the first dose. GLP-1 medications require titration over 16-20 weeks to reach maintenance dose. For patients who need immediate behavioral support (e.g., trying to break a pattern), phentermine's rapid onset can be useful.
Argument 3: GLP-1 intolerance.
About 6-8% of patients discontinue GLP-1 medications due to GI side effects. Phentermine offers an entirely different mechanism for these patients.
Argument 4: Combination strategy.
Phentermine paired with a GLP-1 may produce more weight loss than either alone. The combination strategy is gaining clinical traction even though it lacks formal trial evidence.
Argument 5: Patients who want a finite course of treatment.
Phentermine's 12-week approved course may align with patient preferences for short-term intervention. A patient who does not want to commit to lifelong therapy may choose phentermine for a focused weight-loss push.
The counter: for patients with cardiovascular contraindications, anxiety, or substance abuse history, phentermine is inappropriate regardless of cost. For patients seeking sustained weight loss over years, GLP-1 has more durable trial evidence. The decision is patient-specific.
Decision logic
Cost is the binding constraint: phentermine (or Qsymia for chronic-use option).
Weight-loss target above 10%: GLP-1 (semaglutide or tirzepatide).
Cardiovascular comorbidities: GLP-1 (avoid phentermine).
Cardiovascular protection desired: semaglutide (Wegovy) has FDA CV indication.
Anxiety or insomnia issues: GLP-1 (phentermine often worsens these).
Pregnancy planning: neither during pregnancy; phentermine and topiramate both have teratogenic concerns; GLP-1 not recommended.
History of substance abuse: GLP-1 (phentermine is schedule IV controlled).
Cannot tolerate GLP-1 GI side effects: phentermine or Qsymia as alternative.
Short-term weight loss goal (e.g., pre-surgery, life event): phentermine reasonable for 12-week course.
Long-term weight management goal: GLP-1 has the durability evidence.
Plateaued on GLP-1 monotherapy: consider adding low-dose phentermine if no contraindications.
FAQ
What is the difference between GLP-1 and phentermine? Different drug classes (incretin vs sympathomimetic stimulant), different mechanisms, different durations of approval (chronic vs short-term).
Which produces more weight loss? GLP-1 by a wide margin. Tirzepatide ~22% vs phentermine ~3-5%.
Is phentermine FDA-approved for long-term use? No, only short-term. The combination Qsymia (phentermine + topiramate) is approved for chronic use.
What is the cost comparison? Phentermine $10-$30/month; GLP-1 $200-$1,300/month.
Side effects of each? Phentermine: stimulant effects (insomnia, anxiety, increased HR/BP). GLP-1: GI (nausea, diarrhea).
Can I take both? Yes, with clinician oversight. Combination is increasingly common.
Who should not take phentermine? Patients with cardiovascular disease, uncontrolled hypertension, substance abuse history, anxiety disorders, glaucoma, hyperthyroidism, or pregnancy.
Is one safer long-term? GLP-1 has more long-term safety data and is approved for chronic use.
What is Qsymia? Phentermine + topiramate combination, FDA-approved 2012 for chronic weight management. Bridges between phentermine alone and GLP-1.
Will I regain weight after stopping? Yes, with both. Regain on stopping is well-documented for GLP-1 (STEP 4) and is the reason phentermine alone has only short-term FDA approval.
Which is covered by insurance? Phentermine usually covered with low copay. GLP-1 coverage varies dramatically by plan and indication.
Can phentermine cause heart problems? The current formulation has not been shown to cause valvulopathy (that was specific to fenfluramine, withdrawn in 1997). Cardiovascular contraindications exist due to BP and HR effects, but proper screening minimizes risk.
Sources
- FDA. Phentermine prescribing information. Original approval 1959; subsequent reformulations.
- FDA. Qsymia (phentermine-topiramate ER) prescribing information. Approval 2012.
- Allison DB et al. EQUIP trial: Controlled-Release Phentermine/Topiramate in Severely Obese Adults. Obesity. 2012.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity: STEP 1. New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity: SURMOUNT-1. New England Journal of Medicine. 2022.
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: SURMOUNT-5. New England Journal of Medicine. 2025.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: STEP 4. JAMA. 2021.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes: SELECT. New England Journal of Medicine. 2023.
- Aronne LJ et al. Combined Pharmacotherapy and Lifestyle Intervention for Obesity: Practical Considerations. The Obesity Society. 2024.
- The Obesity Society. Clinical Practice Statement on Pharmacotherapy for Obesity. 2025.
- Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline Update. 2025.
- American Society for Metabolic and Bariatric Surgery. Obesity Pharmacotherapy Position Statement. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform that connects patients with independent licensed clinicians and U.S. pharmacies for GLP-1 medication evaluation. We do not currently coordinate prescriptions for phentermine, Qsymia, or other non-GLP-1 obesity medications through our platform.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved and are not interchangeable with brand-name Wegovy or Zepbound. They are prepared by state-licensed 503A pharmacies in response to individual prescriptions.
Results Disclaimer. Trial results referenced (STEP 1, SURMOUNT-1, SURMOUNT-5, EQUIP) reflect controlled study conditions and population means. Individual results vary based on dose, adherence, lifestyle, baseline biology, and combination strategies. Statements about average outcomes do not predict any specific patient's experience.
Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Qsymia is a registered trademark of Vivus LLC. Saxenda is a registered trademark of Novo Nordisk A/S. Phentermine is a generic medication available under multiple brand and generic names. FormBlends has no commercial relationship with the manufacturers or trial sponsors referenced.